参与单位名称 中信建投证券股份有限公司研究发展部首席食品饮料/农林牧渔行业分析 及人员姓名 师黄付生、中信建投证券股份有限公司研究发展部高级经理/农林牧渔行 业分析师许奇峰、包商银行食品与农业金融事业部行业研究员张晋溢 时间 2016 年 2 月 17 日 15：00- 16：30 地点 东宝生物办公楼会议室 上市公司接待 董事会秘书刘芳、技术总监王富荣、证券部高级经理单华夷 人员姓名 一、公司目前明胶产能 6500 吨，未来将扩产到 10000 吨，公司怎么 看明胶市场？ 答： 投资者关系活 明胶分为骨明胶和皮明胶。公司目前主营骨明胶。主要产品有"金 动主要内容介 鹿"牌胶囊用明胶、食品添加剂明胶。 绍 明胶市场发展趋势： 证券代码：300239 证券简称：东宝生物 包头东宝生物技术股份有限公司投资者关系活动记录表 编号：2016-01 | --- | --- | --- | --- | |--------------|------------------------|---------------------------------|-------| | | | | | | 投资者关系活 | | ■特定对 ...

证券代码：300239 证券简称：东宝生物 编号：2017-001 包头东宝生物技术股份有限公司 投资者关系活动记录表 | --- | --- | --- | |----------------|------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | ■ | 特定对象调研 □分析师会议 | | | □ 媒体采访 □业绩说明会 | | | 投资者关系 | □ 新闻发布会 □路演活动 | | | 活动类别 | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称 | | 国泰君安 孙金钜 吴璋怡 杨萍 刘佳 | | 及人员姓名 | | 深圳清水源投资管理有限公司 蔡秋斌 | | | | 中铁宝盈资产管理有限 ...

编号：2022-003 证券代码：300239 证券简称：东宝生物 包头东宝生物技术股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | |-------------------------|---------------|----------|-----------------------------------------------------------------------------| | | 特定对象调研 | | 分析师会议 | | 投资者关系活动 | □媒体采访 | | 业绩说明会 | | 类别 | □新闻发布会 | | □路演活动 | | | □现场参观 | | | | | 其他 ( | 电话会议 | ) | | | 长城证券 | 黄淑妍 | | | | 银河基金 | 李 | | | 参与单位名称及 人员姓名 | 广发资管 | 刘 | | | | 华富基金 | 陈 | | | | 建银理财 | 施伟锋 | | | 时间 | 2022 年 6 | 月 17 | 16:00 — 17:00 | | 地点 | 线上交流 | | | | 上市公司接待人 | | | ...

证券代码：300239 证券简称：东宝生物 包头东宝生物技术股份有限公司 投资者关系活动记录表 编号：2022-002 | --- | --- | --- | |-------------------------|------------------------------------|-------------------------------------------------------------------| | | 特定对象调研 | 分析师会议 | | 投资者关系活动 | □媒体采访 | 业绩说明会 | | 类别 | □新闻发布会 | □路演活动 | | | □现场参观 | | | | 其他 2022 | "股东来了"走进上市公司——东宝生物 | | 参与单位名称及 人员姓名 | 恒泰证券及个人投资者共 | 15 人； | | 时间 | 2022 年 6 月 15 日 | 09:00-11:00 | | | | | | 地点 | 东宝生物生态园区研发中心一楼会议室 | | | 上市公司接待人 | | 副总经理、董事会秘书单华夷；证券业务主管倪帆 | | 员姓名 | | | | | 一、参观东宝生 ...

Group 1: Company Performance - The company achieved operating revenue of ¥706,043,743.51 in the first three quarters, an increase of 71.26% compared to the same period last year [2] - Net profit attributable to shareholders reached ¥87,784,562.99, up 538.68% year-on-year [2] - Deducting non-recurring gains and losses, the net profit was ¥83,076,138.59, reflecting a significant increase of 1,176.44% compared to the previous year [2] Group 2: Operational Strategies - The company has implemented a dynamic monitoring system for operational indicators, focusing on revenue, net profit, gross margin, and expenses [2] - Emphasis on market expansion and cost control has led to improved asset utilization efficiency [2] - The company has adopted a diversified product strategy and flexible production models to enhance operational efficiency [2] Group 3: Response to Challenges - The company has activated contingency plans in response to the COVID-19 pandemic, ensuring smooth logistics and supply chain management [1] - Measures include strengthening supplier relationships and optimizing inventory management to mitigate risks [1] Group 4: Market Opportunities - The gelatin business is expected to grow due to its wide applications in medical, food, and health products [2] - The company is expanding its market reach by diversifying product applications and enhancing product value [2] - The collagen market is experiencing rapid growth, with increasing applications in health, food, and cosmetics [3] Group 5: Raw Material Management - The company is facing price fluctuations in raw materials due to increased production costs and logistics [3] - Strategies to mitigate risks include diversifying suppliers, optimizing procurement structures, and signing long-term contracts to stabilize prices [3] Group 6: Future Outlook - The company aims to leverage the growth opportunities in the gelatin and collagen markets, focusing on high-quality development and product chain extension [3] - The company is enhancing its marketing efforts through e-commerce and brand promotion strategies to boost sales [4]

Financial Performance - The company's revenue for Q3 2022 reached ¥229,684,681.49, representing a 69.39% increase year-over-year[5] - Net profit attributable to shareholders was ¥29,809,651.68, a significant increase of 381.33% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥27,672,248.86, up 479.52% year-over-year[5] - The basic earnings per share for the period was ¥0.0502, reflecting a 321.85% increase compared to the same quarter last year[5] - The company's operating revenue for Q3 2022 reached ¥706,043,743.51, an increase of 71.26% compared to ¥412,267,239.59 in the same period last year[12] - Operating profit for the quarter was ¥107,490,911.86, compared to ¥17,011,668.55 in the previous year, reflecting a substantial growth[31] - The net profit for the third quarter of 2022 was ¥92,439,092.18, a significant increase from ¥13,670,658.88 in the same period last year, representing a growth of approximately 576%[32] - The net profit attributable to shareholders of the parent company was ¥87,784,562.99, compared to ¥13,744,660.50 in the previous year, indicating a year-over-year increase of about 537%[32] - The basic and diluted earnings per share for the third quarter were both ¥0.1479, up from ¥0.0248 in the prior year, reflecting an increase of approximately 497%[32] Assets and Liabilities - Total assets as of September 30, 2022, amounted to ¥2,219,279,610.42, a 5.07% increase from the end of the previous year[5] - Total liabilities decreased to ¥486,400,284.44 from ¥508,580,671.06, showing improved financial stability[29] - The company's equity attributable to shareholders increased to ¥1,506,877,799.19 from ¥1,422,692,834.57, reflecting a growth of 5.9%[29] - Current assets totaled ¥971,578,588.47, an increase of 8.8% from ¥892,592,899.38[29] - Non-current assets rose to ¥1,247,701,021.95, compared to ¥1,219,647,603.86 at the start of the year[29] Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥126,730,842.75, showing a 401.86% increase[5] - The net cash flow from operating activities increased significantly by 401.86% to ¥126,730,842.75, compared to ¥25,252,201.87 in the previous year[13] - Cash inflow from sales of goods and services was ¥496,962,022.72, compared to ¥249,580,843.04 in the previous year, indicating an increase of about 99.4%[34] - The net cash flow from financing activities was ¥127,868,845.94, down from ¥254,532,800.08 in the same period last year, reflecting a decrease of about 50%[36] - The company reported cash outflows from investing activities totaling ¥167,582,255.61, a decrease from ¥334,263,088.04 in the previous year, showing a reduction of approximately 50%[35] Research and Development - R&D expenses surged by 149.80% to ¥17,057,544.09, up from ¥6,828,546.10, driven by increased investment in research and the inclusion of Yiqing Bio in the consolidated financial statements[12] - Research and development expenses for the quarter were ¥17,057,544.09, significantly higher than ¥6,828,546.10 in the same period last year, indicating a focus on innovation[31] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 23,574, with no preferred shareholders[15] - The top shareholder, Qingdao Guoen Technology Co., Ltd., holds 21.18% of the shares, amounting to 125,711,022 shares[15] Other Financial Metrics - The company reported a significant increase in contract liabilities, which rose by 40.54% to ¥6,741,472.07, indicating higher prepayments from customers[10] - The income tax expense rose dramatically by 362.14% to ¥15,439,361.35, up from ¥3,340,873.70, due to increased profits[12] - The company experienced a significant increase in other income, which rose by 2376.26% to ¥642,902.56, compared to ¥25,962.63 in the previous year[12] - The company reported a net loss from investments of ¥718,952.78, an improvement of 57.09% from a loss of ¥1,675,448.37 in the prior period[12] Corporate Developments - The company completed the employee stock ownership plan, enhancing employee cohesion and corporate culture[21][22] - The company successfully increased capital for its subsidiary Yiqing Bio, completing the industrial and commercial change registration[23] - The company established two new subsidiaries to advance its multi-point terminal business strategy and launched new products including collagen peptide drinks and enzyme powders[25] - The company is actively developing e-commerce live streaming to promote star products and strengthen terminal operations[25] - The company optimized raw material procurement and production efficiency, contributing to improved operational performance[20] - The company merged with its subsidiary Yiqing Bio, resulting in increased sales revenue and profit[20] Audit and Reporting - The third quarter report was not audited, indicating that the figures presented are preliminary and subject to change[37]

Financial Performance - The company's operating revenue for the reporting period was ¥476,359,062.02, representing a 72.18% increase compared to ¥276,670,413.54 in the same period last year[26]. - Net profit attributable to shareholders reached ¥57,974,911.31, a significant increase of 667.73% from ¥7,551,503.43 year-on-year[26]. - The net profit after deducting non-recurring gains and losses was ¥55,403,889.73, up 3,096.24% from ¥1,733,408.58 in the previous year[26]. - The net cash flow from operating activities was ¥108,230,931.16, a remarkable increase of 1,721.51% compared to -¥6,674,707.77 in the same period last year[26]. - Basic and diluted earnings per share were both ¥0.0977, reflecting a 588.03% increase from ¥0.0142[26]. - Total assets at the end of the reporting period were ¥2,187,662,627.21, a 3.57% increase from ¥2,112,240,503.24 at the end of the previous year[26]. - The company's revenue for the reporting period reached ¥476,359,062.02, representing a year-on-year increase of 72.18% due to steady growth in gelatin and collagen product sales[86]. - The operating costs increased to ¥352,976,047.34, a rise of 44.44% compared to the previous year, primarily driven by the increase in revenue[87]. - Research and development expenses surged by 121.01% to ¥20,242,699.19, reflecting the company's commitment to innovation and the inclusion of its subsidiary Yiqing Bio's R&D costs[87]. Market and Industry Trends - The company operates in the biopharmaceutical and health industry, which is a strategic emerging industry encouraged by national policies[34]. - The collagen protein application areas include health food, functional food, cosmetics, and industrial applications, with a projected CAGR of 6.55% for the health food market from 2020 to 2025[37]. - The overall market sales are improving, benefiting the health market's sustained and stable development[37]. - The retail sales of consumer goods in China decreased by 11.1% year-on-year, but in June, it turned positive with a growth of 3.1% year-on-year and 0.53% month-on-month, benefiting the company's product promotion and brand building[38]. - The collagen market is in a rapid development phase, with increasing applications in pharmaceuticals, food and beverages, and cosmetics, presenting growth opportunities for the company[40]. Product Development and Innovation - The company plans to launch a new gelatin product by the end of the year and is expecting clinical approval for its hemostatic materials project[35]. - The company has launched multiple new products in 2022 and established new channels and platforms to enhance its market presence[40]. - New retail products launched in 2022 include collagen peptide powders and various health supplements, catering to diverse consumer needs[51]. - The company is committed to research and development of new products, including functional fertilizers and plant growth stimulants, to support modern agricultural development[49]. - The company launched a series of new products in 2022, including collagen peptide powder and probiotics, aiming to establish a breakthrough in terminal business[62]. - The company is focusing on optimizing production processes and reducing costs while developing high-value-added new products[68]. Strategic Acquisitions and Partnerships - The company has strengthened its core competitiveness and industry leadership by acquiring Yiqing Bio, extending its industrial chain[39]. - Yiqing Bio, a subsidiary, has initiated a new intelligent industrialization project for hollow capsules to meet the growing demand in the pharmaceutical and health product markets[41]. - The company is actively collaborating with high-quality production enterprises to expedite the market launch of the "Yuan Su" series of new products[71]. Marketing and Brand Development - The company has appointed a celebrity spokesperson to boost brand awareness and has implemented diverse promotional strategies[62]. - The company aims to enhance its market influence and increase market share through comprehensive brand promotion strategies[128]. - The company is focusing on building a strong domestic collagen brand, "Yuan Su," to capture a larger market share[128]. Environmental and Social Responsibility - The company is committed to low-carbon green manufacturing, aligning with national strategic planning to reduce carbon emissions[70]. - The company has established an environmental protection management committee and has implemented a comprehensive environmental monitoring plan[141]. - The company actively participates in social responsibility initiatives, contributing over 200,000 yuan in products to aid pandemic relief efforts[144]. Governance and Compliance - The company emphasizes the protection of investor rights and has improved its information disclosure practices[143]. - The company has committed to avoiding unfair related-party transactions, ensuring transparency and fairness in all dealings[149]. - The company has established a governance structure that allows for independent operation and decision-making by its board and management[149]. Future Outlook - The company provided an optimistic outlook for the second half of 2022, projecting a revenue growth of 25% based on current market trends and product demand[152]. - Future guidance indicates a focus on sustainability initiatives, with plans to reduce carbon emissions by 25% over the next three years[152].

Production Capacity and Expansion - The company expanded its production capacity to 13,500 tons/year for gelatin and 4,300 tons/year for collagen, but faces sales risks due to market conditions and inventory levels [9]. - The company plans to expand its production capacity with new projects, including a 3,500-ton gelatin construction project and a 2,000-ton collagen project [31]. - The company plans to expand its capsule production capacity from 30 billion to 60 billion capsules over the next three years, indicating strong growth potential [72]. - The company has committed to invest 114,814.05 million RMB in various projects, with a significant portion allocated to the gelatin expansion project [170]. Financial Performance - The company's operating revenue for 2021 was ¥612,165,671.91, representing a 36.39% increase compared to ¥448,827,791.89 in 2020 [31]. - The net profit attributable to shareholders for 2021 was ¥36,484,130.69, a significant increase of 97.74% from ¥18,450,301.36 in 2020 [31]. - The net profit after deducting non-recurring gains and losses was ¥26,920,029.36, up 127.03% from ¥11,857,395.88 in 2020 [31]. - The total assets at the end of 2021 reached ¥2,112,240,503.24, marking a 48.97% increase from ¥1,417,934,200.36 at the end of 2020 [31]. - The net cash flow from operating activities for 2021 was ¥51,501,086.21, a decrease of 18.42% from ¥63,129,603.25 in 2020 [31]. Product Development and Innovation - In 2021, the company launched new products including beef bone collagen peptides and collagen protein sodium hyaluronate vitamin C powder, with plans for further product releases in 2022 [12]. - The company is focusing on technological innovation and product development in the fields of gelatin and collagen to enhance its competitive edge [48]. - The company is actively developing new products and enhancing its market presence, including launching new products and utilizing celebrity endorsements [48]. - The company has successfully developed a new collagen protein product, "shredded meat" plant-based product, and has made significant progress in the development of ultra-low endotoxin gelatin preparation technology [115]. Market Strategy and Presence - The company aims to strengthen its market presence by establishing trade offices in cities like Hangzhou, Shanghai, and Qingdao to boost sales of raw collagen products [9]. - The company is implementing a "Collagen+" strategy to enhance brand visibility and market share, including the use of celebrity endorsements [13]. - The company is actively expanding its market presence by optimizing product structure and launching new products, while enhancing channel and brand development [58]. - The company plans to enhance its online and offline sales channels, leveraging e-commerce and live streaming platforms to boost brand visibility [181]. Research and Development - The company has invested significantly in R&D, ranking among the top in the industry for new technologies and processes related to collagen and its derivatives [81]. - The company has established multiple research and development platforms, including key laboratories and innovation centers in Inner Mongolia and Qingdao [81]. - The company is collaborating with research institutions to enhance its R&D capabilities, particularly in the field of collagen peptides and their applications [88]. - The company is committed to maintaining high standards in product safety and efficacy, as demonstrated by its research on the toxicological safety of collagen peptides [96]. Acquisitions and Partnerships - The acquisition of Yiqing Bio has been integrated into the company's consolidated financial statements, expanding its operational scale and product range [7]. - The company acquired 60% of Qingdao Yiqing Biotechnology Co., Ltd. on November 30, 2021, which specializes in the production and sales of medicinal capsules, enhancing its position in the biopharmaceutical supply chain [135]. - The company has established partnerships with several universities and research institutions to support the development of bio-organic fertilizers and other products [116]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market reach, with a focus on complementary businesses [92]. Governance and Compliance - The company has established a sound governance structure that complies with the regulations set forth by the China Securities Regulatory Commission [197]. - The board of directors consists of 7 members, including 3 independent directors, and operates in compliance with legal and regulatory requirements [196]. - The company actively communicates with stakeholders, ensuring the protection of their legal rights and interests [197]. - There are no significant discrepancies between the company's governance practices and the relevant laws and regulations [197]. Sustainability and Social Responsibility - The company is focused on sustainable practices, promoting a circular economy and resource recycling systems in line with national policies [56]. - The organic fertilizer segment is gaining traction due to government policies promoting sustainable agriculture, with the company positioned to benefit from this trend [51]. - The company is entering the fertilizer market with a resource utilization project, leveraging unique product advantages to capture opportunities in the agricultural sector [188]. - The company is committed to fostering a corporate culture that aligns with its parent company, enhancing employee engagement and operational efficiency [190].

包头东宝生物技术股份有限公司 2022 年第一季度报告全文 证券代码：300239 证券简称：东宝生物 公告编号：2022-018 包头东宝生物技术股份有限公司 2022 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保 证季度报告中财务信息的真实、准确、完整。 3.第一季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 228,169,864.35 | 138,178,161.95 | 65.13% | | 归属于上市公司股东的净利润（元） | 23,723,318.02 | 4,6 ...

Financial Performance - The company's revenue for Q3 2021 reached ¥135,596,826.05, representing an increase of 18.65% compared to the same period last year[3] - Net profit attributable to shareholders for Q3 2021 was ¥6,193,157.07, a significant increase of 64.31% year-on-year[3] - The basic earnings per share for Q3 2021 was ¥0.0119, up by 65.28% compared to the same quarter last year[3] - Operating revenue increased to ¥412,267,239.59, up 36.93% from ¥301,069,330.26, primarily due to increased sales of gelatin and collagen products[10] - The company achieved operating revenue of ¥412,267,239.59, an increase of 36.93% year-over-year, and a net profit attributable to shareholders of ¥13,744,660.50, up 30.30% year-over-year[20] - Net profit for Q3 2021 was CNY 13,670,658.88, representing a 31.0% increase from CNY 10,369,752.85 in Q3 2020[29] Assets and Liabilities - Total assets as of September 30, 2021, amounted to ¥1,615,264,326.62, reflecting a growth of 13.92% from the end of the previous year[3] - The company's total liabilities decreased to CNY 215,370,256.95 from CNY 419,750,969.84 year-on-year[28] - The company reduced short-term borrowings to ¥39,825,314.15 from ¥90,916,828.04 at the end of 2020[26] Cash Flow - The company's cash flow from operating activities for the year-to-date period decreased by 24.99% to ¥25,252,201.87[3] - Cash received from operating activities decreased by 45.16% to ¥7,662,867.40 from ¥13,972,579.86, mainly due to reduced government subsidies[11] - The net cash flow from operating activities for Q3 2021 was ¥25,252,201.87, a decrease from ¥33,666,271.86 in the previous year[33] - The net cash flow from investing activities was -¥121,263,088.04, compared to -¥120,247,612.20 in the same period last year[33] - The net cash flow from financing activities increased to ¥254,532,800.08 from ¥86,936,547.36 year-over-year[33] Equity and Shareholding - The company reported a 41.41% increase in total equity attributable to shareholders, reaching ¥1,399,894,069.67 compared to the end of the previous year[3] - The number of ordinary shareholders at the end of the reporting period was 28,272, with no preferred shareholders[14] - The company has a shareholding structure where the top 10 shareholders include significant stakes from state-owned and private entities, indicating a diverse ownership base[15] - The report indicates that the company has implemented a three-year unlocking schedule for equity incentive shares, with unlocking ratios of 40%, 30%, and 30%[18] Investments and Expenditures - Research and development expenses increased by 80.76% to ¥10,133,540.77, driven by new project investments[8] - The company completed the acquisition of a 60% stake in Qingdao Yiqing Biotechnology Co., Ltd. for a total consideration of ¥27,186.39 million, aiming to enhance its health industry layout and core competitiveness[22] - Investment cash outflows surged by 1230.59% to ¥74,406,780.00 from ¥5,592,000.00, primarily due to increased equity investment expenditures[11] Other Financial Metrics - Other income surged by 79.18% to ¥8,303,857.10 from ¥4,634,464.64, mainly due to increased government subsidies and deferred income[10] - Investment income reported a loss of ¥1,675,448.37, worsening by 47.28% compared to a loss of ¥1,137,626.38, attributed to recognized investment losses from long-term equity investments[10] - Cash paid for various taxes increased by 149.30% to ¥28,605,143.89 from ¥11,474,236.26, driven by higher operating revenue and profit[11] Share Restrictions and Governance - The report highlights that the company is subject to restrictions on share transfers for executives, limiting annual transfers to 25% of their holdings[18] - The company has not disclosed any related party relationships among the top shareholders, which may impact governance and control[15] - The report indicates that the company is preparing for the release of restricted shares on December 15, 2021, for several shareholders, which may affect stock liquidity[18]